Table 4.
The number and proportion of patients who persisted with, switched from, discontinued, or restarted index treatment at month 6 and month 12
| Cohort | Characteristics | Ranibizumab cohort | Aflibercept cohort |
|---|---|---|---|
| Month 6 (180 days) | Total number of patients (primary analysis set) | 2412 (100%) | 1711 (100%) |
| Persisted with index treatment | 1235 (51.2%) | 959 (56.0%) | |
| Switched to comparator treatment | 133 (5.5%) | 25 (1.5%) | |
| Discontinued index treatment | 969 (40.2%) | 678 (39.6%) | |
| Restarted index treatment | 75 (3.1%) | 49 (2.9%) | |
| Month 12 (360 days) | Total number of patients (primary analysis set) | 1758 (100%) | 1119 (100%) |
| Persisted with index treatment | 578 (32.9%) | 483 (43.2%) | |
| Switched to comparator treatment | 179 (10.2%) | 26 (2.3%) | |
| Discontinued index treatment | 855 (48.6%) | 512 (45.8%) | |
| Restarted index treatment | 146 (8.3%) | 98 (8.8%) |
The number of patients refers to the patients in the primary analysis set